Author
Zhang, Fuming; Sun, Peilong; Munoz, Eva; Chi, Lianli; Sakai, Shinobu; Toida, Toshihiko; Zhang, Haifeng; Mousa, Shaker; Linhardt, Robert J.
Other Contributors
Date Issued
2006-06-15
Subject
Biology; Chemistry and chemical biology; Chemical and biological engineering; Biomedical engineering
Degree
Terms of Use
In Copyright : this Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). https://rightsstatements.org/page/InC/1.0/;
Full Citation
Microscale Isolation and Analysis of Heparin from Plasma using an Anion Exchange Spin Column, F. Zhang, P. Sun, E. Mu“oz, L.Chi, S. Sakai, T. Toida, H. Zhang, S. Mousa R. J. Linhardt, Analytical Biochemistry, 353, 284–286, 2006.
Abstract
Heparin, a linear highly sulfated polysaccharide, is a member of the glycosaminoglycan (GAG)1 family [1,2]. Since the 1930s, heparin has been widely used as a clinical anticoagulant [3,4]. More recently, low-molecular weight heparin (LMWH) derivatives have come into widespread use as anticoagulant and antithrombotic drugs [5]. Although heparin’s clinical use predated the establishment of the US. Food and Drug Administration (FDA), the approval of LMWH required a number of pharmacological studies on these new drugs. The pharmacologically relevant concentration of heparin and LMWH in plasma is between 0.1 and 1.0 anti-factor XaU/ml, corresponding to approximately 1–10 µg/ml of drug [6]. Plasma is a complex mixture, making the direct analysis of heparin or LMWH at these concentrations exceedingly challenging. Thus, most of the pharmacological studies of heparin and LMWH have relied on bioassays such as anti-factor Xa activity to evaluate these agents, providing only pharmacodynamic data. This inability to obtain pharmacokinetic data on LMWH is a serious concern because the plasma anti-factor Xa activity of LMWH does not correlate well with its therapeutic efficacy [7].;
Description
Analytical Biochemistry, 353, 284–286; Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
Department
The Linhardt Research Labs.; The Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS);
Publisher
Elsevier
Relationships
The Linhardt Research Labs Online Collection; Rensselaer Polytechnic Institute, Troy, NY; Analytical Biochemistry; https://harc.rpi.edu/;
Access
A full text version is available in DSpace@RPI;